Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-01-29 Declaration of Voting R…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Number of shares and votes in Xspray Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a change in the number of shares and votes due to the exercise of warrants under an incentive program. This directly relates to a change in the company's capital structure (share capital increase). This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it involves warrants, the core event being reported is the resulting change in the total number of shares outstanding and the associated share capital adjustment. It is not a general financing announcement (CAP) but a specific update on the share count.
2021-01-29 English
Warrant holders exercise all warrants within the framework of the incentive program
Share Issue/Capital Change Classification · 99% confidence The document announces that warrant holders, including the CEO, have exercised their warrants to subscribe for new shares, resulting in an increase in the total number of shares and votes. This action directly relates to changes in the company's capital structure through the issuance of new shares following warrant exercise. This fits the definition of 'Share Issue/Capital Change' (SHA). While it involves insider transactions (CEO dealing), the primary corporate action being announced is the capital increase resulting from the warrant exercise, not just the insider trade itself. It is not a general earnings release (ER), a formal annual report (10-K), or a dividend notice (DIV).
2021-01-26 English
Optionsinnehavare utnyttjar samtliga teckningsoptioner inom ramen för incitamentsprogram
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Xspray Pharma AB announcing that its CEO and other option holders have fully exercised their warrants under the LTIP 2015/2021 program. This action results in an increase in the number of shares and votes in the company. The content focuses on the exercise of options, resulting share changes, and insider investment details (including sales to cover taxes and lock-up agreements). This directly relates to changes in the company's capital structure and share count due to employee incentive programs. This fits best under 'Share Issue/Capital Change' (SHA), as the exercise of options leads to the issuance of new shares, increasing the total share count. It is not a general financing announcement (CAP) but a specific change in the number of outstanding shares.
2021-01-26 Swedish
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started
Regulatory Filings Classification · 90% confidence The document announces a specific corporate event: the start of bioequivalence studies for a modified drug formulation (HyNap-Dasa) intended for future market approval applications (ANDA in the USA). It discusses clinical trial progress, expected timelines for preliminary results (Q2), and quotes the CEO regarding strategy. This content relates to ongoing product development and clinical pipeline updates, which is typical for investor relations communication. It is not a formal financial report (10-K, IR, ER), a management change announcement (MANG), or a shareholder vote result (DVA). Since it is a specific update on product development and clinical trials, it fits best under general Investor Relations or a specific regulatory/corporate update. Given the options, it is a specific corporate announcement that doesn't fit the defined financial reports or governance documents. It is most closely aligned with general corporate news dissemination, which often falls under Regulatory Filings (RNS) if no better fit exists, or potentially a specialized Investor Presentation (IP) if it were a slide deck, but here it reads like a press release. Since it is a specific, non-financial, non-governance update, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback category for this type of operational news release.
2021-01-22 English
Xspray Pharmas studie med modifierad formulering av HyNap-Dasa har nu startats
Regulatory Filings Classification · 95% confidence The document is a short announcement from Xspray Pharma regarding the start of bioequivalence studies for a modified formulation of their drug candidate, HyNap-Dasa, intended for an ANDA submission in the USA. It provides key updates on clinical trial progress and expected timelines (Q2 results). The document is brief (3444 characters) and explicitly mentions attached files/links (though the link is external in the provided text structure, the nature of the content is an update announcement). This structure—a brief press release detailing a specific corporate/clinical event—is characteristic of a general regulatory announcement or press release, rather than a comprehensive financial report (10-K, IR) or a dedicated management discussion (MDA). Since it is an announcement of a specific corporate event (clinical trial start/update) and doesn't fit the specific financial/governance codes, the most appropriate general category is Regulatory Filings (RNS), as it functions as a mandatory disclosure to the market about operational progress.
2021-01-22 Swedish
Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)
Regulatory Filings Classification · 95% confidence The document text is an announcement from Xspray Pharma regarding study results and updates on upcoming regulatory applications (ANDA and 505(b)(2) submissions). It details clinical trial timelines, product development progress, and mentions the obligation to make the information public under the EU Market Abuse Regulation. Crucially, the document ends with an 'Attachments' section containing a link to the full document, indicating this text is an announcement *about* the information rather than the comprehensive report itself. Since it is a regulatory announcement providing material updates that don't fit specific categories like ER, IR, or DIRS, and it is not a proxy statement (DEF 14A) or a formal annual report (10-K), the most appropriate classification based on the provided definitions and the 'Menu vs Meal' rule is Regulatory Filings (RNS), which serves as a general regulatory announcement fallback.
2021-01-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.